Knowledge Distillery

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been postulated to affect susceptibility to COVID-19.…

In this paper recently published in the European Journal of Neurology, the authors aimed to determine the frequency and distribution of currently…

Case fatality rates (CFR) of the novel 2019 coronavirus disease (COVID-19) have been reported ranging between 0% to 40% among Parkinson’s disease (PD)…

The objective of this study was to evaluate patient perspectives regarding the use of natalizumab and anti-CD20 therapies (rituximab and ocrelizumab)…

The objective of this study, recently published in Journal of Parkinson’s Disease, was to rapidly identify areas of need to help improve care in…

The objective of this case-control study was to estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S…

The objective of this population based cohort study was to assess rates of cardiovascular and haemostatic events in the first 28 days after…

After the emergence of COVID-19, studies reported a decrease in hospitalizations of patients with ischemic stroke (IS), but there are little to no…

Pregnant women are at increased risk of morbidity and mortality from COVID-19 but have been excluded from the phase 3 COVID-19 vaccine trials. Data on…

Reports indicate an increased risk of ischemic stroke during coronavirus disease 2019 (COVID-19) infection.

Venous thromboembolism (VTE) is a common complication of COVID-19. It is not well understood how hospitals have managed VTE prevention and the effect…

Myalgia, increased levels of creatine kinase, and persistent muscle weakness have been reported in patients with COVID-19. The objective of this…